-
1
-
-
0037010474
-
Selected major risk factors and global and regional burden of disease
-
Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk factors and global and regional burden of disease. Lancet. 2002;360(9343):1347-1360.
-
(2002)
Lancet
, vol.360
, Issue.9343
, pp. 1347-1360
-
-
Ezzati, M.1
Lopez, A.D.2
Rodgers, A.3
Vander Hoorn, S.4
Murray, C.J.5
-
2
-
-
0003731907
-
Reducing Risks, Promoting Healthy Life
-
World Health Organization, Available at, Accessed September 17, 2008
-
World Health Organization. Reducing Risks, Promoting Healthy Life. The World Health Report. Available at: http://www.who.int/whr/2002/ en/whr02_en.pdf. Accessed September 17, 2008.
-
The World Health Report
-
-
-
3
-
-
12344282783
-
Global burden of hypertension: Analysis of worldwide data
-
Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365(9455):217-223.
-
(2005)
Lancet
, vol.365
, Issue.9455
, pp. 217-223
-
-
Kearney, P.M.1
Whelton, M.2
Reynolds, K.3
Muntner, P.4
Whelton, P.K.5
He, J.6
-
4
-
-
33847633400
-
Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004
-
Ong KL, Cheung BM, Man YB, Lau CP, Lam KS. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension. 2007;49(1):69-75.
-
(2007)
Hypertension
, vol.49
, Issue.1
, pp. 69-75
-
-
Ong, K.L.1
Cheung, B.M.2
Man, Y.B.3
Lau, C.P.4
Lam, K.S.5
-
5
-
-
0038047699
-
Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States
-
Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA. 2003;289(18):2363-2369.
-
(2003)
JAMA
, vol.289
, Issue.18
, pp. 2363-2369
-
-
Wolf-Maier, K.1
Cooper, R.S.2
Banegas, J.R.3
-
6
-
-
44949104716
-
Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension
-
Smith DH. Comparison of angiotensin II type 1 receptor antagonists in the treatment of essential hypertension. Drugs. 2008;68(9): 1207-1225.
-
(2008)
Drugs
, vol.68
, Issue.9
, pp. 1207-1225
-
-
Smith, D.H.1
-
7
-
-
0029886630
-
Blood pressure as a cardiovascular risk factor: Prevention and treatment
-
Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA. 1996;275(20):1571-1576.
-
(1996)
JAMA
, vol.275
, Issue.20
, pp. 1571-1576
-
-
Kannel, W.B.1
-
8
-
-
0030034592
-
Blood pressure and end-stage renal disease in men
-
Klag MJ, Whelton PK, Randall BL, et al. Blood pressure and end-stage renal disease in men. N Engl J Med. 1996;334(1):13-18.
-
(1996)
N Engl J Med
, vol.334
, Issue.1
, pp. 13-18
-
-
Klag, M.J.1
Whelton, P.K.2
Randall, B.L.3
-
9
-
-
70449851433
-
Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document
-
Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27: 2121-2158.
-
(2009)
J Hypertens
, vol.27
, pp. 2121-2158
-
-
Mancia, G.1
Laurent, S.2
Agabiti-Rosei, E.3
-
10
-
-
0344373794
-
Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
-
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group
-
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288(23): 2981-2997.
-
(2002)
JAMA
, vol.288
, Issue.23
, pp. 2981-2997
-
-
-
11
-
-
62849090492
-
Hypertension Improvement Project (HIP): Study protocol and implementation challenges
-
Dolor RJ, Yancy WS Jr, Owen WF, et al. Hypertension Improvement Project (HIP): study protocol and implementation challenges. Trials. 2009;10:13.
-
(2009)
Trials
, vol.10
, pp. 13
-
-
Dolor, R.J.1
Yancy Jr., W.S.2
Owen, W.F.3
-
12
-
-
0030056841
-
New meta-analysis of treatment trials of hypertension: Improving the estimate of therapeutic benefit
-
Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Hum Hypertens. 1996;10(1):1-8.
-
(1996)
J Hum Hypertens
, vol.10
, Issue.1
, pp. 1-8
-
-
Gueyffier, F.1
Froment, A.2
Gouton, M.3
-
13
-
-
0031044480
-
Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis
-
Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA. 1997;277(9):739-745.
-
(1997)
JAMA
, vol.277
, Issue.9
, pp. 739-745
-
-
Psaty, B.M.1
Smith, N.L.2
Siscovick, D.S.3
-
14
-
-
0025831464
-
Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group
-
SHEP Cooperative Research Group
-
SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group. JAMA. 1991; 265(24):3255-3264.
-
(1991)
JAMA
, vol.265
, Issue.24
, pp. 3255-3264
-
-
-
15
-
-
33846485050
-
Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States
-
Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med. 2007;167(2):141-147.
-
(2007)
Arch Intern Med
, vol.167
, Issue.2
, pp. 141-147
-
-
Wang, Y.R.1
Alexander, G.C.2
Stafford, R.S.3
-
16
-
-
9144248446
-
Hypertension treatment and control in five European countries, Canada, and the United States
-
Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension. 2004;43(1):10-17.
-
(2004)
Hypertension
, vol.43
, Issue.1
, pp. 10-17
-
-
Wolf-Maier, K.1
Cooper, R.S.2
Kramer, H.3
-
17
-
-
36649026223
-
Achieving blood pressure goals: Why aren't we?
-
Cushman WC, Basile J. Achieving blood pressure goals: why aren't we? J Clin Hypertens (Greenwich). 2006;8(12):865-872.
-
(2006)
J Clin Hypertens (Greenwich)
, vol.8
, Issue.12
, pp. 865-872
-
-
Cushman, W.C.1
Basile, J.2
-
19
-
-
2942750248
-
Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension
-
Spranger CB, Ries AJ, Berge CA, Radford NB, Victor RG. Identifying gaps between guidelines and clinical practice in the evaluation and treatment of patients with hypertension. Am J Med. 2004;117(1): 14-18.
-
(2004)
Am J Med
, vol.117
, Issue.1
, pp. 14-18
-
-
Spranger, C.B.1
Ries, A.J.2
Berge, C.A.3
Radford, N.B.4
Victor, R.G.5
-
20
-
-
5444220883
-
Pharmacogenetics of antihypertensive drug response
-
Kreutz R. Pharmacogenetics of antihypertensive drug response. Curr Hypertens Rep. 2004;6(1):15-20.
-
(2004)
Curr Hypertens Rep
, vol.6
, Issue.1
, pp. 15-20
-
-
Kreutz, R.1
-
21
-
-
0032882634
-
Low-dose antihypertensive combination therapy: Its rationale and role in cardiovascular risk management
-
Neutel JM. Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management. Am J Hypertens. 1999;12(8 Pt 2):73S-79S.
-
(1999)
Am J Hypertens
, vol.12
, Issue.8 PART 2
-
-
Neutel, J.M.1
-
22
-
-
61649091385
-
Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials
-
Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009;122(3): 290-300.
-
(2009)
Am J Med
, vol.122
, Issue.3
, pp. 290-300
-
-
Wald, D.S.1
Law, M.2
Morris, J.K.3
Bestwick, J.P.4
Wald, N.J.5
-
23
-
-
24644443331
-
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial
-
Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906.
-
(2005)
Lancet
, vol.366
, Issue.9489
, pp. 895-906
-
-
Dahlof, B.1
Sever, P.S.2
Poulter, N.R.3
-
24
-
-
57349138291
-
Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients
-
Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359(23):2417-2428.
-
(2008)
N Engl J Med
, vol.359
, Issue.23
, pp. 2417-2428
-
-
Jamerson, K.1
Weber, M.A.2
Bakris, G.L.3
-
25
-
-
2942635317
-
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
-
Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426): 2022-2031.
-
(2004)
Lancet
, vol.363
, Issue.9426
, pp. 2022-2031
-
-
Julius, S.1
Kjeldsen, S.E.2
Weber, M.3
-
26
-
-
77951735232
-
Effects of intensive blood-pressure control in type 2 diabetes mellitus
-
Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010; 362(17):1575-1585.
-
(2010)
N Engl J Med
, vol.362
, Issue.17
, pp. 1575-1585
-
-
Cushman, W.C.1
Evans, G.W.2
Byington, R.P.3
-
28
-
-
68149162414
-
Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension
-
Bramlage P. Fixed-dose combinations of renin-angiotensin blocking agents with calcium channel blockers or hydrochlorothiazide in the treatment of hypertension. Expert Opin Pharmacother. 2009;10(11): 1755-1767.
-
(2009)
Expert Opin Pharmacother
, vol.10
, Issue.11
, pp. 1755-1767
-
-
Bramlage, P.1
-
29
-
-
77149134656
-
The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm
-
Schmieder RE. The role of fixed-dose combination therapy with drugs that target the renin-angiotensin system in the hypertension paradigm. Clin Exp Hypertens. 2010;32(1):35-42.
-
(2010)
Clin Exp Hypertens
, vol.32
, Issue.1
, pp. 35-42
-
-
Schmieder, R.E.1
-
30
-
-
74949125742
-
Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: A meta-analysis
-
Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effectiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension. 2010;55(2):399-407.
-
(2010)
Hypertension
, vol.55
, Issue.2
, pp. 399-407
-
-
Gupta, A.K.1
Arshad, S.2
Poulter, N.R.3
-
31
-
-
0037490085
-
Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials
-
Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br Med J. 2003;326(7404):1427.
-
(2003)
Br Med J
, vol.326
, Issue.7404
, pp. 1427
-
-
Law, M.R.1
Wald, N.J.2
Morris, J.K.3
Jordan, R.E.4
-
32
-
-
0028845276
-
Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: A randomized, double-blind, placebocontrolled, parallel-group study. The Benazepril/Amlodipine Study Group
-
Frishman WH, Ram CV, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebocontrolled, parallel-group study. The Benazepril/Amlodipine Study Group. J Clin Pharmacol. 1995;35(11):1060-1066.
-
(1995)
J Clin Pharmacol
, vol.35
, Issue.11
, pp. 1060-1066
-
-
Frishman, W.H.1
Ram, C.V.2
McMahon, F.G.3
-
33
-
-
0030513239
-
Treatment of patients with essential hypertension: Amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo
-
Kuschnir E, Acuna E, Sevilla D, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther. 1996;18(6):1213-1224.
-
(1996)
Clin Ther
, vol.18
, Issue.6
, pp. 1213-1224
-
-
Kuschnir, E.1
Acuna, E.2
Sevilla, D.3
-
34
-
-
42049107348
-
Telmisartan, ramipril, or both in patients at high risk for vascular events
-
Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15): 1547-1559.
-
(2008)
N Engl J Med
, vol.358
, Issue.15
, pp. 1547-1559
-
-
Yusuf, S.1
Teo, K.K.2
Pogue, J.3
-
35
-
-
45849124200
-
Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors
-
Miller DR, Oliveria SA, Berlowitz DR, Fincke BG, Stang P, Lillienfeld DE. Angioedema incidence in US veterans initiating angiotensin-converting enzyme inhibitors. Hypertension. 2008;51(6):1624-1630.
-
(2008)
Hypertension
, vol.51
, Issue.6
, pp. 1624-1630
-
-
Miller, D.R.1
Oliveria, S.A.2
Berlowitz, D.R.3
Fincke, B.G.4
Stang, P.5
Lillienfeld, D.E.6
-
36
-
-
33748930983
-
-
National Institute for Health and Clinical Excellence, Available at, Accessed June 9, 2010
-
National Institute for Health and Clinical Excellence. Hypertension: Management of hypertension in adults in primary care. Available at: http://www.nice.org.uk/nicemedia/live/10986/30114/30114.pdf. Accessed June 9, 2010.
-
Hypertension: Management of hypertension in adults in primary care
-
-
-
37
-
-
34250370923
-
Antihypertensive activity of angiotensin II AT1 receptor antagonists: A systematic review of studies with 24 h ambulatory blood pressure monitoring
-
Fabia MJ, Abdilla N, Oltra R, Fernandez C, Redon J. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens. 2007;25(7):1327-1336.
-
(2007)
J Hypertens
, vol.25
, Issue.7
, pp. 1327-1336
-
-
Fabia, M.J.1
Abdilla, N.2
Oltra, R.3
Fernandez, C.4
Redon, J.5
-
38
-
-
77149136418
-
Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans
-
Coltamai L, Maillard M, Simon A, Vogt B, Burnier M. Comparative vascular and renal tubular effects of angiotensin II receptor blockers combined with a thiazide diuretic in humans. J Hypertens. 2010;28(3): 520-526.
-
(2010)
J Hypertens
, vol.28
, Issue.3
, pp. 520-526
-
-
Coltamai, L.1
Maillard, M.2
Simon, A.3
Vogt, B.4
Burnier, M.5
-
39
-
-
28144458569
-
Sustained 24-hour blockade of the renin-angiotensin system: A high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor
-
Hasler C, Nussberger J, Maillard M, Forclaz A, Brunner HR, Burnier M. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor. Clin Pharmacol Ther. 2005;78(5):501-507.
-
(2005)
Clin Pharmacol Ther
, vol.78
, Issue.5
, pp. 501-507
-
-
Hasler, C.1
Nussberger, J.2
Maillard, M.3
Forclaz, A.4
Brunner, H.R.5
Burnier, M.6
-
40
-
-
34547454237
-
Effects of angiotensin receptor blockers on ambulatory plasma renin activity in healthy, normal subjects during unrestricted sodium intake
-
Jones MR, Sealey JE, Laragh JH. Effects of angiotensin receptor blockers on ambulatory plasma renin activity in healthy, normal subjects during unrestricted sodium intake. Am J Hypertens. 2007;20(8): 907-916.
-
(2007)
Am J Hypertens
, vol.20
, Issue.8
, pp. 907-916
-
-
Jones, M.R.1
Sealey, J.E.2
Laragh, J.H.3
-
41
-
-
0043172552
-
Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension
-
Brunner HR, Stumpe KO, Januszewicz A. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil assessed by 24-hour ambulatory blood pressure monitoring in patients with essential hypertension. Clin Drug Invest. 2003;23(7):419-430.
-
(2003)
Clin Drug Invest
, vol.23
, Issue.7
, pp. 419-430
-
-
Brunner, H.R.1
Stumpe, K.O.2
Januszewicz, A.3
-
42
-
-
0034760610
-
Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension
-
Oparil S, Williams D, Chrysant SG, Marbury TC, Neutel J. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich). 2001;3(5): 283-291, 318.
-
(2001)
J Clin Hypertens (Greenwich)
, vol.3
, Issue.5
-
-
Oparil, S.1
Williams, D.2
Chrysant, S.G.3
Marbury, T.C.4
Neutel, J.5
-
43
-
-
12744269551
-
Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: A comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan
-
Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs. 2005;5(1):41-50.
-
(2005)
Am J Cardiovasc Drugs
, vol.5
, Issue.1
, pp. 41-50
-
-
Smith, D.H.1
Dubiel, R.2
Jones, M.3
-
44
-
-
44949171907
-
Olmesartan medoxomil: A review of its use in the management of hypertension
-
Scott LJ, McCormack PL. Olmesartan medoxomil: a review of its use in the management of hypertension. Drugs. 2008;68(9): 1239-1272.
-
(2008)
Drugs
, vol.68
, Issue.9
, pp. 1239-1272
-
-
Scott, L.J.1
McCormack, P.L.2
-
45
-
-
0029049389
-
Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease
-
Haria M, Wagstaff AJ. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease. Drugs. 1995;50(3):560-586.
-
(1995)
Drugs
, vol.50
, Issue.3
, pp. 560-586
-
-
Haria, M.1
Wagstaff, A.J.2
-
46
-
-
43549100189
-
The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebocontrolled, 8-week factorial efficacy and safety study
-
Chrysant S, Melino M, Karki S, Lee J, Heyrman R. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebocontrolled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30(4):587-604.
-
(2008)
Clin Ther
, vol.30
, Issue.4
, pp. 587-604
-
-
Chrysant, S.1
Melino, M.2
Karki, S.3
Lee, J.4
Heyrman, R.5
-
47
-
-
73349111840
-
Onset of antihypertensive effect in patients with mild-to-severe hypertension treated with a combination of amlodipine besylate and olmesartan medoxomil compared with component monotherapy and placebo
-
Chrysant S, Melino M, Karki S, Lee J, Heyrman R. Onset of antihypertensive effect in patients with mild-to-severe hypertension treated with a combination of amlodipine besylate and olmesartan medoxomil compared with component monotherapy and placebo. J Clin Hypertens. 2008a;26:378 Suppl 1:378.
-
(2008)
J Clin Hypertens
, vol.26
, Issue.378 SUPPL. 1
, pp. 378
-
-
Chrysant, S.1
Melino, M.2
Karki, S.3
Lee, J.4
Heyrman, R.5
-
48
-
-
74349114056
-
Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: Evaluation by baseline hypertension stage and prior antihypertensive medication use
-
Oparil S, Lee J, Karki S, Melino M. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use. J Cardiovasc Pharmacol. 2009;54(5):427-436.
-
(2009)
J Cardiovasc Pharmacol
, vol.54
, Issue.5
, pp. 427-436
-
-
Oparil, S.1
Lee, J.2
Karki, S.3
Melino, M.4
-
49
-
-
57449086215
-
Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: A randomized, double-blind, parallel-group, multicentre study
-
Volpe M, Brommer P, Haag U, Miele C. Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29(1):11-25.
-
(2009)
Clin Drug Investig
, vol.29
, Issue.1
, pp. 11-25
-
-
Volpe, M.1
Brommer, P.2
Haag, U.3
Miele, C.4
-
50
-
-
67650302856
-
Olmesartan medoxomil plus amlodipine increases eff icacy in patients with moderate-to-severe hypertension after monotherapy: A randomized, double-blind, parallel-group, multicentre study
-
Barrios V, Brommer P, Haag U, Calderon A, Escobar C. Olmesartan medoxomil plus amlodipine increases eff icacy in patients with moderate-to-severe hypertension after monotherapy: a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29(7):427-439.
-
(2009)
Clin Drug Investig
, vol.29
, Issue.7
, pp. 427-439
-
-
Barrios, V.1
Brommer, P.2
Haag, U.3
Calderon, A.4
Escobar, C.5
-
51
-
-
84868588276
-
Effects on BP control of amlodipine (AML)/olmesartan medoxomil (OM), with or without hydrochlorothiazide (HCTZ), in patients not controlled by prior antihypertensive monotherapy (late breaker at the American Society of Hypertension 25th Annual Scentific Meeting, New York)
-
Weir MR, Hsueh WA, Nesbitt SD, et al. Effects on BP control of amlodipine (AML)/olmesartan medoxomil (OM), with or without hydrochlorothiazide (HCTZ), in patients not controlled by prior antihypertensive monotherapy (late breaker at the American Society of Hypertension 25th Annual Scentific Meeting, New York). J Clin Hypertens (Greenwich). 2010;12(7):536.
-
(2010)
J Clin Hypertens (Greenwich)
, vol.12
, Issue.7
, pp. 536
-
-
Weir, M.R.1
Hsueh, W.A.2
Nesbitt, S.D.3
-
52
-
-
77955396612
-
Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: The AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study
-
Punzi H, Neutel JM, Kereiakes DJ, et al. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study. Ther Adv Cardiovasc Dis. 2010;4(4):209-221.
-
(2010)
Ther Adv Cardiovasc Dis
, vol.4
, Issue.4
, pp. 209-221
-
-
Punzi, H.1
Neutel, J.M.2
Kereiakes, D.J.3
-
53
-
-
70349973807
-
Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension
-
Chrysant SG, Oparil S, Melino M, Karki S, Lee J, Heyrman R. Efficacy and safety of long-term treatment with the combination of amlodipine besylate and olmesartan medoxomil in patients with hypertension. J Clin Hypertens (Greenwich). 2009;11(9):475-482.
-
(2009)
J Clin Hypertens (Greenwich)
, vol.11
, Issue.9
, pp. 475-482
-
-
Chrysant, S.G.1
Oparil, S.2
Melino, M.3
Karki, S.4
Lee, J.5
Heyrman, R.6
-
54
-
-
75749092819
-
Olmesartan medoxomil/amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy-additional effect by uptitration in patients with moderate-to-severe hypertension
-
Heagerty AM, Laeis P, Haag U. Olmesartan medoxomil/amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy-additional effect by uptitration in patients with moderate-to-severe hypertension. J Hypertens. 2009;27 Suppl 4:S283.
-
(2009)
J Hypertens
, vol.27
, Issue.SUPPL. 4
-
-
Heagerty, A.M.1
Laeis, P.2
Haag, U.3
-
55
-
-
84898892067
-
Olmesartan medoxomil/amlodipine (OLM/AML) improves blood pressure (BP) control throughout 24 hours compared with AML monotherapy in patients with moderate-to-severe hypertension
-
Parati G, Bilo G. Olmesartan medoxomil/amlodipine (OLM/AML) improves blood pressure (BP) control throughout 24 hours compared with AML monotherapy in patients with moderate-to-severe hypertension. J Hypertens. 2010;28:e111.
-
(2010)
J Hypertens
, vol.28
-
-
Parati, G.1
Bilo, G.2
-
56
-
-
75749092819
-
Olmesartan medoxomil/amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy-additional effect by uptitration in patients with moderate-to-severe hypertension
-
Heagerty AM, Laeis P, Haag U. Olmesartan medoxomil/amlodipine (OLM/AML) provides 24-hour antihypertensive efficacy-additional effect by uptitration in patients with moderate-to-severe hypertension. J Hypertens. 2009;27 Suppl 4:S283.
-
(2009)
J Hypertens
, vol.27
, Issue.SUPPL. 4
-
-
Heagerty, A.M.1
Laeis, P.2
Haag, U.3
-
57
-
-
67549119235
-
Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: An open-label, long-term study
-
Volpe M, Miele C, Haag U. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study. Clin Drug Investig. 2009;29(6):381-391.
-
(2009)
Clin Drug Investig
, vol.29
, Issue.6
, pp. 381-391
-
-
Volpe, M.1
Miele, C.2
Haag, U.3
-
58
-
-
67549116889
-
Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: Post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study
-
Mourad JJ, Le Jeune S. Effective systolic blood pressure reduction with olmesartan medoxomil/amlodipine combination therapy: post hoc analysis of data from a randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 2009;29(6):419-425.
-
(2009)
Clin Drug Investig
, vol.29
, Issue.6
, pp. 419-425
-
-
Mourad, J.J.1
Le Jeune, S.2
-
59
-
-
84898855739
-
Effects on BP control of amlodipine (AML)/olmesartan medoxomil (OM), with or without hydrochlorothiazide (HCTZ), in patients not controlled by prior antihypertensive monotherapy
-
New York, Presented as a
-
Weir M, Hsueh WA, Nesbitt SD, et al. Effects on BP control of amlodipine (AML)/olmesartan medoxomil (OM), with or without hydrochlorothiazide (HCTZ), in patients not controlled by prior antihypertensive monotherapy. 2010: Presented as a late breaker at the American Society of Hypertension 25th Annual Scentific Meeting and Exposition 2010: New York.
-
(2010)
Late breaker at the American Society of Hypertension 25th Annual Scentific Meeting and Exposition 2010
-
-
Weir, M.1
Hsueh, W.A.2
Nesbitt, S.D.3
-
60
-
-
0031018599
-
Pharmacological differences between calcium antagonists
-
Opie LH. Pharmacological differences between calcium antagonists. Eur Heart J. 1997;18 Suppl A:A71-A79.
-
(1997)
Eur Heart J
, vol.18
, Issue.SUPPL. A
-
-
Opie, L.H.1
|